LucasInvest
VIEN
← Explore US stocks

US equities · SEC fundamentals

AMGEN INC

AMGN · CIK 0000318154 · Biological Products, (No Diagnostic Substances)

Source: SEC EDGAR/XBRL

Revenue

USD

36.8B USD

Period data
PeriodValue
FY 202126B USD
FY 202226.3B USD
FY 202328.2B USD
FY 202433.4B USD
FY 202536.8B USD

Operating income

USD

9.1B USD

Period data
PeriodValue
FY 20217.6B USD
FY 20229.6B USD
FY 20237.9B USD
FY 20247.3B USD
FY 20259.1B USD

Net income

USD

7.7B USD

Period data
PeriodValue
FY 20215.9B USD
FY 20226.6B USD
FY 20236.7B USD
FY 20244.1B USD
FY 20257.7B USD

Total assets

USD

90.6B USD

Period data
PeriodValue
FY 202161.2B USD
FY 202265.1B USD
FY 202397.2B USD
FY 202491.8B USD
FY 202590.6B USD

Equity

USD

8.7B USD

Period data
PeriodValue
FY 20216.7B USD
FY 20223.7B USD
FY 20236.2B USD
FY 20245.9B USD
FY 20258.7B USD

Operating cash flow

USD

10B USD

Period data
PeriodValue
FY 20219.3B USD
FY 20229.7B USD
FY 20238.5B USD
FY 202411.5B USD
FY 202510B USD

Revenue growth

%

10%

Period data
PeriodValue
FY 20212.2%
FY 20221.3%
FY 20237.1%
FY 202418.6%
FY 202510%

Operating income growth

%

25.1%

Period data
PeriodValue
FY 2021-16.4%
FY 202225.2%
FY 2023-17.4%
FY 2024-8.1%
FY 202525.1%

Net income growth

%

88.5%

Period data
PeriodValue
FY 2021-18.9%
FY 202211.2%
FY 20232.5%
FY 2024-39.1%
FY 202588.5%

Operating margin

%

24.7%

Period data
PeriodValue
FY 202129.4%
FY 202236.3%
FY 202328%
FY 202421.7%
FY 202524.7%

Net margin

%

21%

Period data
PeriodValue
FY 202122.7%
FY 202224.9%
FY 202323.8%
FY 202412.2%
FY 202521%

Return on assets

%

8.5%

Period data
PeriodValue
FY 20219.5%
FY 202210.4%
FY 20238.3%
FY 20244.3%
FY 20258.5%

Debt/Equity

x

No applicable data available

Period data
PeriodValue
FY 2021N/A
FY 2022N/A
FY 2023N/A
FY 2024N/A
FY 2025N/A